A controlled trial of digoxin in congestive heart failure.

Machine translation Machine translation
类别 Primary study
期刊The American journal of cardiology
Year 1988
連結 Pubmed, DOI
由于地高辛从检查在充血性心力衰竭的作用（瑞士法郎）窦性心律病人的研究结果相互矛盾，交叉进行过试验，其中20例7调整到1.54的水平高辛周2.56 nmol /升7周匹配的安慰剂。对处理顺序是由随机分配和病人，临床医生和研究人员被忽视的分配。在病情不断恶化，治疗期间被终止，结果量测指标。如果恶化，在第一个时期发生的，病人越过代码没有被打破。七名病人必需的，因为越来越多的研究期间瑞士法郎症状过早终止。在全部7时服用安慰剂（p = 0.016）。呼吸困难的微小差异（p值= 0.044），行走测试评分（P = 0.055），临床评估瑞士法郎（p值= 0.036）和射血分数（p = 0.004）赞同地高辛治疗组。更严重的心衰患者更可能受益于高辛管理。得出的结论是口服地高辛，在调整到生产出1.54〜2.56 nmol血清窦性心律一些在CHF患者/升，生活和运动能力的功能质量的提高剂量。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: 074281a7c5a11b322d94274a5e6ff9c363677649
First added on: Jun 08, 2011
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use